The Next Cox-2 Battle: Merck, Novartis Drugs Face Vocal Resistance
This article was originally published in RPM Report
Executive Summary
Novartis AG and Merck & Co. Inc. beware: Steven Nissen doesn't want your investigational cox-2 inhibitors to win approval from the Food & Drug Administration.